Want to see CTKB full AI Analyst Report?
Top Page
Cytek Biosciences
(NASDAQ:CTKB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.00
▼(-10.31% Downside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by deteriorating profitability and negative cash flow despite strong recent revenue growth and a low-debt balance sheet. Technicals add pressure as the stock trades below major moving averages with negative momentum. Guidance and H2 improvement expectations provide some support, but losses, elevated operating costs, and one-time items reduce visibility.
Positive Factors
Installed base & recurring revenue expansion
A growing installed base (3,933 units, +142 added in the quarter) and recurring revenue of 35% of LTM create durable pull-through for reagents, service and software. This installed-base-driven model supports predictable repeat sales and strengthens long-term revenue visibility and customer stickiness.
Negative Factors
Deteriorating profitability and cash conversion
Deeply negative net margin (~-39%) and negative operating and free cash flow signal that revenue growth currently does not convert into cash. If losses and cash burn persist, the company may face funding pressure or delayed investments, weakening financial flexibility over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Installed base & recurring revenue expansion
A growing installed base (3,933 units, +142 added in the quarter) and recurring revenue of 35% of LTM create durable pull-through for reagents, service and software. This installed-base-driven model supports predictable repeat sales and strengthens long-term revenue visibility and customer stickiness.
Read all positive factors
Cytek Biosciences (CTKB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$544.98M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue Growth3.61%
EPS Growth-568.29%
CountryUS
Employees700
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.62
Shares Outstanding129,142,600
10 Day Avg. Volume768,350
30 Day Avg. Volume1,731,532
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.69Price Target Upside27.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$208.83M
Cytek Biosciences Business Overview & Revenue Model
Company Description
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Light...
How the Company Makes Money
Cytek primarily generates revenue by selling flow cytometry instruments (capital equipment) and then monetizing the installed base through recurring, higher-frequency purchases tied to instrument usage and ownership. Key revenue streams include: (...
Cytek Biosciences Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but cautiously constructive picture: revenue growth (6% YoY) driven by strong performance in the U.S. and China, expansion of installed base, growing recurring revenue (35% of LTM), and strategic product launches (Borealis and Aurora Evo) underpin future upside. Offsetting these positives are widening GAAP losses, a Q2 adjusted EBITDA decline, regional weaknesses in EMEA and parts of APAC, rising operating expenses (including litigation-related G&A increases), and some one-time items (tariff refund, investment write-off) that cloud margin comparability. Management raised the low end of guidance and expects H2 improvement, but several challenges (regional budgetary pressures, delayed clinical penetration in the U.S., and reorganization timeline) temper near-term outlook.Positive Updates
Quarterly Revenue Growth
Q2 2026 revenue of $48.1 million, up 6% year-over-year (compared to $45.6M in Q2 2025).
Negative Updates
Widening GAAP Net Loss
GAAP net loss of $12.2 million in Q2 2026 versus $5.6 million in Q2 2025, reflecting higher operating loss, lower other income, and a tax expense versus prior year tax benefit.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Q2 2026 revenue of $48.1 million, up 6% year-over-year (compared to $45.6M in Q2 2025).
Read all positive updates
Company Guidance
Cytek raised the low end of its full‑year 2026 revenue guidance to $207–$212 million (midpoint up $1 million) assuming no change in currency rates and said revenue should be significantly higher in Q4 versus Q3 per normal seasonality; management expects adjusted EBITDA to be roughly break‑even for 2026 with improvement in H2 after a Q2 adjusted EBITDA loss of $1.5 million (Q2 GAAP net loss $12.2 million), Q2 revenue was $48.1 million (+6% YoY), and free cash flow was approximately neutral. They said gross margins (excluding a $2.8 million tariff refund) should increase as revenue rises—Q2 GAAP gross margin was 59% (53% excl. refund), adjusted gross margin was 61% (56% excl. refund), product margin was 60% (52% excl. refund) and service margin was 56%—cash and marketable securities totaled $262 million as of June 30, 2026, and recurring revenue represented 35% of trailing 12‑month revenue.Cytek Biosciences Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 206.71M | 201.49M | 200.45M | 193.01M | 164.04M | 127.95M |
| Gross Profit | 110.03M | 104.46M | 111.11M | 109.43M | 100.97M | 79.14M |
| EBITDA | -30.14M | -17.39M | 4.79M | -4.41M | 9.49M | 8.92M |
| Net Income | -80.58M | -66.54M | -6.02M | -12.15M | 2.58M | 3.00M |
Balance Sheet | ||||||
| Total Assets | 446.93M | 461.54M | 499.50M | 494.46M | 519.48M | 463.31M |
| Cash, Cash Equivalents and Short-Term Investments | 262.00M | 261.53M | 277.86M | 262.41M | 341.15M | 364.62M |
| Total Debt | 26.46M | 23.74M | 17.02M | 14.14M | 18.09M | 0.00 |
| Total Liabilities | 124.98M | 119.80M | 103.76M | 101.39M | 93.93M | 57.92M |
| Stockholders Equity | 321.95M | 341.74M | 395.74M | 393.06M | 425.30M | 405.04M |
Cash Flow | ||||||
| Free Cash Flow | -16.98M | -8.77M | 21.85M | 454.00K | -22.10M | 266.00K |
| Operating Cash Flow | -8.77M | -4.69M | 25.38M | 5.28M | -12.23M | 4.63M |
| Investing Cash Flow | -30.06M | 10.12M | -82.97M | -93.89M | -55.91M | -20.99M |
| Financing Cash Flow | 7.86M | -13.43M | -15.82M | -41.81M | 5.51M | 213.56M |
Cytek Biosciences Technical Analysis
Negative
4.46
Price Trends
4.31
Negative
4.34
Negative
4.58
Negative
Market Momentum
-0.03
Positive
39.33
Neutral
23.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Negative. The current price of 4.46 is below the 20-day moving average (MA) of 4.48, above the 50-day MA of 4.31, and below the 200-day MA of 4.58, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 39.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTKB.
Cytek Biosciences Risk Analysis
Cytek Biosciences disclosed 73 risk factors in its most recent earnings report. Cytek Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cytek Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.10B | 31.11 | 28.39% | ― | 1.52% | ― | |
63 Neutral | $787.64M | -45.78 | -8.23% | ― | 16.77% | 39.26% | |
58 Neutral | $1.86B | -24.57 | -38.36% | ― | 28.14% | -5.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $544.98M | -7.31 | -20.77% | ― | 3.61% | -568.29% | |
47 Neutral | $471.10M | -5.61 | -17.61% | ― | 3.63% | -93.57% | |
43 Neutral | $434.84M | -3.26 | -488.45% | ― | 5.04% | 81.29% |
* Healthcare Sector Average
CTKB
Cytek Biosciences
4.16
0.05
1.22%
PACB
Pacific Biosciences
1.17
-0.09
-7.54%
VREX
Varex Imaging
12.25
4.44
56.85%
SIBN
SI-Bone
18.14
1.82
11.15%
BFLY
Butterfly Network
8.30
6.91
497.12%
BVS
Bioventus
13.98
7.05
101.73%
Cytek Biosciences Corporate Events
Executive/Board Changes
Cytek Biosciences Announces Chief Legal Officer Transition
Neutral
Jun 25, 2026
Cytek Biosciences, Inc. announced that Chief Legal Officer and Corporate Secretary Valerie Barnett will leave her position effective June 29, 2026, following a mutual agreement reached on June 18, 2026. The company emphasized that Barnett’s ...
Executive/Board ChangesShareholder Meetings
Cytek Biosciences Stockholders Back Board, Pay and Auditor
Positive
Jun 16, 2026
On June 10, 2026, Cytek Biosciences, Inc. held its 2026 annual meeting of stockholders, with approximately 86.1% of outstanding common shares represented, reflecting strong investor engagement in the company’s corporate governance. Stockhold...
Executive/Board Changes
Cytek Biosciences Announces Resignation of Senior Sales Executive
Neutral
Jun 2, 2026
On May 27, 2026, Cytek Biosciences, Inc. announced that Philippe Busque, Ph.D., submitted his resignation as Senior Vice President, Global Sales and Services, effective June 5, 2026. The departure, which the company said is to allow him to pursue ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.